ARVs Water Impact: Examining the Environmental Consequences of Antiretroviral Drugs in South Africa’s Water Systems

By João L. Carapinha

July 29, 2025

A study by North-West University found high levels of HIV antiretrovirals (ARVs) in South African water systems. The ARVs lopinavir and efavirenz were detected downstream of wastewater plants, exceeding safety limits. These pose risks to aquatic life, such as altered snail development and disrupted bacteriophages. Authorities claim current standards protect human health.

Key Insights

Lopinavir and efavirenz were the most common ARVs found, at 38 μg/L and 24 μg/L. Wastewater systems cannot remove these drugs, and the resultant environmental effects include bacterial blooms and harm to non-target species. Long-term risks to ecosystems and humans are unclear.

South Africa’s HIV program uses about 159,000 kg of ARVs yearly. Around 30% enters water via sewage, and treatment plants are not designed to filter these drugs. Global research labels ARVs as contaminants of concern and current standards ignore such pollutants.

Implications

This crisis requires interdisciplinary solutions:

  1. Better wastewater tech (e.g., advanced oxidation) may help but could be costly.
  2. New regulations should set ARV discharge limits for environmental safety.
  3. Ongoing monitoring is needed to track risks like antimicrobial resistance.

The study highlights the balance between public health and environmental protection. Cross-sector collaboration is vital. For more, review the original findings on ARVs water impact.

Reference url

Recent Posts

PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment

By João L. Carapinha

May 19, 2026

New data from the PSMAddition study indicate that Pluvicto combined with standard of care, consisting of an androgen receptor pathway inhibitor plus androgen deprivation therapy, produced a 58% lower risk of prostate-specific antigen progression compared with standard of care alone. Patients rece...
Financing Boosts Vaccine Manufacturing Africa: New Facility to Enhance Local Production Capacity
In a major step forward for vaccine manufacturing Africa, Biovac has secured a financing package from the International Finance Corporation (IFC), the EIB Group, and the European Commission to build the continent’s first end-to-end multi-vaccine production facility. Landmark Funding ...
Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvant Settings

By João L. Carapinha

May 18, 2026

Enhertu breast cancer treatment has secured FDA approval for neoadjuvant use in adults with HER2-positive Stage II or III disease before surgery, followed by taxane plus trastuzumab and pertuzumab, and for adjuvant therapy in patients with residual invasive disease after prior trastuzumab-based r...